CEO & Cofounder, Radicle Science
BIOGRAPHY
MAR 23, 2022 9:00 AM PDT
Keynote Presentation: Preliminary Results from the Radicle Science ACES Study, History's Largest Longitudinal Trial of CBD Products
Presented at:
Cannabis Sciences Virtual Event Series 2022
Speaker
Abstract
Radicle Science's ACES (Advancing CBD Education & Science) study was an IRB approved 4 week, 14 arm, open label randomized clinical trial of 13 CBD products plus a waitlist control group, involving nearly 3,000 diverse participants, assessing validated outcome measures of well being, quality of life, pain, sleep, and anxiety, and tracking usage behavior and side effects.
Learning Objectives:
1. Discuss current knowledge of the therapeutic potential of CBD.
2. Evaluate the current regulatory landscape for CBD in the U.S. and the mislabeling of products.
3. Assess lessons from the ACES study regarding the product attributes most associated with improvements.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...